Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carly Koelsch

Nurse Practitioner, Adult Health Sarasota, FL Nurse Practitioner

NPI 1982900098 CMS profile 10807286

2089 Hawthorne St, Suite 200, Sarasota, FL 34239

Open in the dashboard

General payments

$264,777

1,064 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carly Koelsch of Sarasota, FL is reported in the CMS Open Payments database as having received $264,777 across 1,064 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $84,102 215
2024 General $99,135 280
2023 General $33,913 204
2022 General $32,354 221
2021 General $15,272 144

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carly Koelsch
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Carly Koelsch were reported at $84,102. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Carly Koelsch Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $15,272 $138 $43–$438 $132
2022 $32,354 $165 $54–$494 $149
2023 $33,913 $178 $61–$549 $160
2024 $99,135 $186 $62–$575 $164
2025 $84,102 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $150,151 440 payments
  2. Lilly USA, LLC $95,435 247 payments
  3. Eli Lilly and Company $10,289 28 payments
  4. E.R. Squibb & Sons, L.L.C. $1,987 8 payments
  5. Celgene Corporation $1,223 31 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $971 58 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $677 38 payments
  8. Genzyme Corporation $548 20 payments
  9. Janssen Biotech, Inc. $519 35 payments
  10. Ironwood Pharmaceuticals, Inc $408 20 payments
  11. Other $2,569 139 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $172,103 162 payments
  2. Travel and Lodging $53,986 156 payments
  3. Food and Beverage $20,760 729 payments
  4. Consulting Fee $17,887 15 payments
  5. Education $42 2 payments
Products named General payments · program years 2021–2025
  1. OMVOH $70,261 144 payments
  2. RINVOQ $35,239 151 payments
  3. SKYRIZI Immunology $28,248 88 payments
  4. SKYRIZI Immunology $27,095 59 payments
  5. HUMIRA $8,692 43 payments
  6. CREON $3,164 50 payments
  7. ZEPOSIA $1,306 33 payments
  8. XIFAXAN $924 54 payments
  9. LINZESS $740 47 payments
  10. DUPIXENT $548 20 payments
  11. Other $5,689 334 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,823

Median for Nurse Practitioner: 389

Drug cost

$307,684

Median for Nurse Practitioner: $21,885

Branded share of claims

21.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 19 $126,373
Linzess Linaclotide Brand 62 $50,118
Xifaxan Rifaximin Brand 18 $43,190
Mesalamine Generic 47 $27,496
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 118 $19,006
Omeprazole Generic 652 $9,664
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 91 $5,419
Famotidine Generic 360 $4,789
Budesonide Dr Budesonide Brand 39 $4,023
Dexlansoprazole Dr Dexlansoprazole Brand 11 $3,939

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$111,792

Medicare's payments for the services billed

Medicare patients

1,078

Average age 76

Services billed

1,607

628 women, 450 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 58%
Ischemic heart disease 40%
Diabetes 23%
Cancer 23%
Osteoporosis 23%
Atrial fibrillation 22%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OMVOH
$42,307 — —
SKYRIZI
$16,552 — —
RINVOQ
$8,331 — —
DUPIXENT
$163 — —
XIFAXAN
$129 18 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

1,064 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record